[1] |
LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin.
Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
|
[2] |
LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin.
The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
|
[3] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[4] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi .
PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
|
[5] |
WANG Jie, LI Long, CHEN Feng, LIU Shengfei.
Research progress of metformin in the pathogenesis of pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
|
[6] |
SHEN Chang, AI Kelong, HU Changping.
Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
|
[7] |
FU Hong, TIAN Lei.
Individualized precision therapy for patients with ischemic stroke and hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
|
[8] |
CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong.
Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
|
[9] |
SUN Ying, YU Qin.
Research progress on the imbalance of coagulation and fibrinolysis system and the pathogenesis and treatment of idiopathic pulmonary interstitial fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 689-695.
|
[10] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi.
Integrins targeting αv are used as drug targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 709-714.
|
[11] |
LI Xueheng, LI Long.
Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
|
[12] |
ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang.
Application of chronopharmacology in the hypertension treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
|
[13] |
CUI Sumei, CUI Zhaoqiang.
Application of β-blockers for hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
|
[14] |
LI Yuanfang, CUI Zhaoqiang.
Treatment of hypertension complicated with hyperuricemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
|
[15] |
XU Jianfei, LIN Li.
Research progress in pharmacological and non-pharmacological treatments of hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
|